We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vindon H. | LSE:VDN | London | Ordinary Share | GB00B06N4S86 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 13.25 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/7/2015 16:40 | SBS now nudging 16p and another acquisition target announced | buywell3 | |
31/10/2013 22:22 | SBS now trading at 10.75p Sellers of VDN stock that ploughed their cash into SBS shares would have done OK it seems | buywell2 | |
11/10/2013 22:07 | So no interims from Vindon and no dividend Presumably the profit and dividend payment that were to happen now get ploughed into SBS , now trading at 10p | buywell2 | |
18/9/2013 17:18 | The 'squeeze' .... OFFER CLOSING FOR FURTHER ACCEPTANCES AND COMPULSORY ACQUISITION OF VINDON SHARES On 17 September 2013, Source BioScience announced that its recommended cash offer to acquire the entire issued and to be issued share capital of Vindon had been declared unconditional in all respects. Source BioScience today announces that the Offer will be closed to further acceptances with effect from 2 October 2013. Source BioScience has today implemented the procedure under Chapter 3 of Part 28 of the Companies Act 2006 to compulsorily acquire all of the outstanding Vindon Shares which it does not already hold or has not already acquired, contracted to acquire or in respect of which it has not already received valid acceptances. Letters have been sent to non-assenting Vindon Shareholders informing them of the intended exercise by Source BioScience of its right under section 979 of the Companies Act 2006 (the "Act") to 'squeeze-out' such Vindon Shareholders, together with a notice of such action pursuant to section 980(1) of the Act. Settlement of the consideration to which any Vindon Shareholders (or, in the absence of any contrary direction as specified in the Offer Document, the first named shareholder in the case of joint shareholders) are entitled under the Offer will be effected (in the manner set out in paragraph 20 of Part II of the Offer Document): (i) in the case of acceptances received on or before 13 September 2013, complete in all respects, by 27 September 2013 or, (ii) in the case of acceptances received, complete in all respects, after 13 September 2013 but on or before 2 October 2013, within 14 days of such receipt. Non-assenting shareholders who do not accept the Offer by 2 October 2013 will not receive payment until after compulsory purchase has been implemented on 30 October 2013. ... | piedro | |
13/9/2013 13:19 | .................... Vindon Flexible approach to cabinet manufacture We often tailor our manufacturing expertise according to clients' demands and market requirements: We have provided a temperature-only photostability cabinet to operate from 4-40ºC. We simply adapted a standard 5799 cabinet and four reach-in chambers, capable of being moved without being stripped down. We also manufactured a temperature and humidity cycling cabinet to operate at -30 to +60ºC, we modified a 5804-SM cabinet to include increased insulation and direct refrigeration, as well as adding a slide actuator and programmable controller. .................... Temperature and humidity cycling service Vindon has a new service available now in the UK and available soon at our USA and Ireland facilities. This comprises a wide range of state-of-the art environmental test facilities to simulate temperature and humidity conditions, replicating natural and man-made climatic environments. In order to assess the ability of client samples to withstand exposure to several environmental conditions, we have recently added temperature and humidity cycling testing. source; Linkedin .................... | piedro | |
02/9/2013 11:47 | Mr Yeung Yu Loong has now increased his SBS holding to 5.55% Any VDN holders or ex-holders have any comments on Source BioSciences. | piedro | |
29/8/2013 08:46 | '' Source BioScience said its 13.7p a share offer for Vindon Healthcare had received valid acceptances totalling 82.9% of that company's issued share capital. It extended its offer to Sept. 11 '' Source Bioscience H1 pretax profit rises to £0.6m 29 August 2013 | 08:14am Source Bioscience's first-half pretax profit rises to £0.6 million, from £0.4 million. Revenue rose to £8.8 million, from £8.4 million. "The encouraging first half of the year represents a continuation of the strong growth and business performance achieved last year and reflects the substantial opportunities we see for further development across both our Healthcare and LifeSciences divisions," said chairman Laurie Turnbull in a statement. Separately, Source BioScience said its 13.7p a share offer for Vindon Healthcare had received valid acceptances totalling 82.9% of that company's issued share capital. It extended its offer to Sept. 11. www.stockmarketwire. | buywell2 | |
29/8/2013 07:45 | Vindon is going to belong to Source BioScience Piedro That you have most likely lost money on your investment is not my fault and is no excuse for being rude What you have to decide is whether you want to become a SBS shareholder, if you believe enough in the Vindon story that you have written here on advfn thus far that you still want to carry on with it albeit under another name but still with the VDN CEO on the board Check out SBS results today | buywell2 | |
25/8/2013 13:24 | buywell2, I don't think you are doing any favours to SBS coming on this thread and spouting sensationalism. Please moderate your tone and present the facts as facts with their rightful reference links and your opinion as your opinion which may be distinguished by IMO or IMHO etc to avoid confusion. | piedro | |
24/8/2013 08:28 | All SBS AGM resolutions passed ... it's a done deal Source BioScience will start offering ''Over Night''/''Same Day'' DNA Sequencing Services from BOTH Vindon California (West Coast Life Sciences Pharma Biotech hub and Vindon Atlanta ( East Coast Life Sciences Pharma Biotech hub) most likely by the end of September. For starters Read yesterdays new about NHS UK to open Hospitals in India ..... lots of new opportunities | buywell2 | |
22/8/2013 07:29 | Have you sold your VDN shares Piedro yet ? | buywell2 | |
20/8/2013 08:51 | Won't happen If you read the SBS prospectus re the takeover BIG Institutions that have backed the offer include Hendeson Global have UPPED their stake to circa 12.5% from current 5.5% plus Artemis have just arrived taking a maiden circa 8.5% Legal and General add to stay at 8% plus at least 3 more who have added to stay at around 6% Even SBS management/staff and Directors add to stay at just over 6% This is a done deal Institutions like those will look after their investment, the only thing that might upset the applecart is voting on resolutions 1, 2, 3, 4 by SBS shareholders While you are at it Take a butchers at my Cyprotex thread (CRX) BIG Institutional buying there also recently | buywell2 | |
19/8/2013 12:20 | Re: Ian Yeung Thank you for the confirmation Those 8.5m shares give more weight to his arguments Certainly the share price has taken a tumble since the offer. 8p/share would be interesting. | piedro | |
19/8/2013 11:56 | buywell2 Re: "I take it you read my posts ... " I confess to having some difficulty reading your SBS posts; - finding a confusion in distinguishing between "quotations", ''quotations'' and your personal opinions. - headers and following text disconnected. - line spacing can be erratic. - the links are not activate-able. eg: www.uk.advfn.com/cmn vs: Thus, I do not give the attention to them that they possibly deserve. No offense intended, it's just the way I work. P. | piedro | |
19/8/2013 08:11 | My logic ran thus .... If you were a fan of Vindon , then I thought you would be a fan of the company that bought them with a view of increasing both Vindons sales and Source BioSciences sales by X selling to each others clients. Re that article again you posted That Ian Yeung is in fact the same Ian Yu Loong Yeung , a Physician educated in Cambridge 2001 and 2002 coming out with a MB , ex Hong Kong , who recently took a 4% plus stake in SBS about a month back. I take it you read my posts on the positive growth projections for the 'cold storage' business re Pharmas/Hospitals/re | buywell2 | |
16/8/2013 13:34 | I admit to not having done much research on SBS Why do you think that I "need to do more"? I have no interest in the company except as a passing curiosity. [edited] | piedro | |
16/8/2013 10:47 | Then you need to do more research Piedro ... read their interims next week to see how struggling they are Do you feel you have been sold down the river by your BoD ? | buywell2 | |
15/8/2013 11:49 | Thank you, Mr. Yeung was of the opposition note then. He does make some interesting points which are well worth being considered by SBS shareholders - IMHO In the offer document (downloadable from the VDN website) it is stated that SBS intends to continue with Vindon's current activities and that their places of business and fixed assets will remain unchanged. Also most of Vindon's directors and senior management will remain in the enlarged group As Mr. Yeung points out, this will change the nature of SBS and suggest to me that perhaps they also are struggling to find their niche | piedro | |
15/8/2013 10:58 | Piedro from the link YOU posted but obviously never read in post 254 And posted on the SBS thread. You do know I trust running this Vindon thread that they OUTSOURCE the manufacture of cold cabinets/Rooms do you not ? I don't think you will get to see Interims ..... acquisition event will probably kick in prior to that. I do hope the Vindon BoD sink their dough into SBS stock .... would show faith in their Vindon Products Here is what Ian Yeung said from YOUR unread link Member Ian Yeung has said: SBS is in the business of cell biology,histopatholo But if you look, a fair amount of Vindon's money comes from the manufacture of steel cabinets and rooms for laboratories. The points I would like to raise are: 1. Personally I feel that this kind of thing sounds more like an engineering/ manufacturing type business. And I don't think it's entirely matches up to what SBS does as a cell biology/genetic sequencing company. | buywell2 | |
15/8/2013 10:46 | Interim Results should be out this month | piedro | |
15/8/2013 10:34 | Please excuse my ignorance ... Who is Ian Yeung? | piedro | |
15/8/2013 07:29 | Course they do .... they love it That Ian Yeung guy is a bit out of kilter with what Vindon do They OUTSOURCE the contstruction of cold cabinets/rooms and then use in house staff to add value to the carcass back at the ranch piedro Do you think any of the BoD will be buyers of SBS shares using their new wedge ? | buywell2 | |
13/8/2013 11:45 | Spot the Clown. Do the Americans like this sort of Circus? | piedro | |
12/8/2013 16:00 | Article in the ShareSoc Informer re: Source BioScience offer for VDN hxxp://www.sharesoc. ... you may need to register to read the article (free) ... not everyone is in agreement | piedro |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions